NGLFINE

What NGL Fine-Chem promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q4 FY26

what the last two calls moved 10 tracked 1 delivered 2 missed 7 open
  • US FDA Initial Filing delivered said Q4 FY25 Promised: Targeted in the October to December quarter [CY25] Q4 FY26: Promise remains achieved. No new updates.
  • EU Sales from Existing Plant missed said Q4 FY25 Promised: INR25 crores to INR30 crores in the current year [FY26] Q4 FY26: No FY26 EU sales figure was reported. Management now anticipates European business to start in H2 FY27, contradicting the INR25-30 crore target for FY26.
  • Capex Completion Timeline delayed said Q4 FY25 Promised: Completion is targeted for Q3 of the current financial year [FY26] Q4 FY26: Commissioning further delayed from Q1 FY27 to early Q2 FY27 due to gas and labor shortages.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 10 tracked commitments for NGL Fine-Chem — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens